Review
The interplay between p66Shc, reactive oxygen species and cancer cell metabolism
Magdalena Lebiedzinska-Arciszewska,
Monika Oparka,
Ignacio Vega-Naredo,
Agnieszka Karkucinska-Wieckowska,
Paolo Pinton,
Jerzy Duszynski,
Mariusz R. Wieckowski,
Magdalena Lebiedzinska-Arciszewska
Department of Biochemistry, Nencki Institute of Experimental Biology, Warsaw, Poland
Equal contribution.Search for more papers by this authorMonika Oparka
Department of Biochemistry, Nencki Institute of Experimental Biology, Warsaw, Poland
Equal contribution.Search for more papers by this authorIgnacio Vega-Naredo
Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal
Search for more papers by this authorAgnieszka Karkucinska-Wieckowska
Department of Pathology, The Children's Memorial Health Institute, Warsaw, Poland
Search for more papers by this authorPaolo Pinton
Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara, Italy
Search for more papers by this authorJerzy Duszynski
Department of Biochemistry, Nencki Institute of Experimental Biology, Warsaw, Poland
Search for more papers by this authorCorresponding Author
Mariusz R. Wieckowski
Department of Biochemistry, Nencki Institute of Experimental Biology, Warsaw, Poland
Correspondence to: Mariusz R. Wieckowski, Department of Biochemistry, Nencki Institute of Experimental Biology, Polish Academy of Sciences, 3 Pasteur Street, 02-093 Warsaw, Poland Tel: (048) 22 589-23-72 Fax: (048) 22 822-53-42 e-mail: [email protected]Search for more papers by this authorMagdalena Lebiedzinska-Arciszewska,
Monika Oparka,
Ignacio Vega-Naredo,
Agnieszka Karkucinska-Wieckowska,
Paolo Pinton,
Jerzy Duszynski,
Mariusz R. Wieckowski,
Magdalena Lebiedzinska-Arciszewska
Department of Biochemistry, Nencki Institute of Experimental Biology, Warsaw, Poland
Equal contribution.Search for more papers by this authorMonika Oparka
Department of Biochemistry, Nencki Institute of Experimental Biology, Warsaw, Poland
Equal contribution.Search for more papers by this authorIgnacio Vega-Naredo
Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal
Search for more papers by this authorAgnieszka Karkucinska-Wieckowska
Department of Pathology, The Children's Memorial Health Institute, Warsaw, Poland
Search for more papers by this authorPaolo Pinton
Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara, Italy
Search for more papers by this authorJerzy Duszynski
Department of Biochemistry, Nencki Institute of Experimental Biology, Warsaw, Poland
Search for more papers by this authorCorresponding Author
Mariusz R. Wieckowski
Department of Biochemistry, Nencki Institute of Experimental Biology, Warsaw, Poland
Correspondence to: Mariusz R. Wieckowski, Department of Biochemistry, Nencki Institute of Experimental Biology, Polish Academy of Sciences, 3 Pasteur Street, 02-093 Warsaw, Poland Tel: (048) 22 589-23-72 Fax: (048) 22 822-53-42 e-mail: [email protected]Search for more papers by this authorAbstract
The adaptor protein p66Shc links membrane receptors to intracellular signalling pathways and has the potential to respond to energy status changes and regulate mitogenic signalling. Initially reported to mediate growth signals in normal and cancer cells, p66Shc has also been recognized as a pro-apoptotic protein involved in the cellular response to oxidative stress. Moreover, it is a key element in processes such as cancer cell proliferation, tumor progression, metastasis and metabolic reprogramming. Recent findings on the role of p66Shc in the above-mentioned processes have been obtained through the use of various tumor cell types, including prostate, breast, ovarian, lung, colon, skin and thyroid cancer cells. Interestingly, the impact of p66Shc on the proliferation rate was mainly observed in prostate tumors, while its impact on metastasis was mainly found in breast cancers. In this review, we summarize the current knowledge about the possible roles of p66Shc in different cancers.
References
- 1Shen N, Tsao BP. Current advances in the human lupus genetics. Curr Rheumatol Rep 2004; 6: 391–8.
- 2Pelicci G, Lanfrancone L, Grignani F, McGlade J, Cavallo F, Forni G et al. A novel transforming protein (SHC) with an SH2 domain is implicated in mitogenic signal transduction. Cell 1992; 70: 93–104.
- 3Luzi L, Confalonieri S, Di Fiore PP, Pelicci PG. Evolution of Shc functions from nematode to human. Curr Opin Genet Dev 2000; 6: 668–74.
- 4Migliaccio E, Giorgio M, Pelicci PG. Apoptosis and aging: role of p66Shc redox protein. Antioxid Redox Signal 2006; 8: 600–8.
- 5Natalicchio A, Tortosa F, Perrini S, Laviola L, Giorgino F. p66Shc, a multifaceted protein linking Erk signalling, glucose metabolism, and oxidative stress. Arch Physiol Biochem 2011; 117: 116–24.
- 6Purdom S, Chen QM. p66(Shc): at the crossroad of oxidative stress and the genetics of aging. Trends Mol Med 2003; 9: 206–10.
- 7Trinei M, Berniakovich I, Beltrami E, Migliaccio E, Fassina A, Pelicci P et al. P66Shc signals to age. Aging (Albany NY) 2009; 1: 503–10.
- 8Suski JM, Karkucinska-Wieckowska A, Lebiedzinska M, Giorgi C, Szczepanowska J, Szabadkai G et al. p66Shc aging protein in control of fibroblasts cell fate. Int J Mol Sci 2011; 12: 5373–89.
- 9Pinton P, Rizzuto R. p66Shc, oxidative stress and aging: importing a lifespan determinant into mitochondria. Cell Cycle 2008; 7: 304–8.
- 10Giorgio M, Migliaccio E, Orsini F, Paolucci D, Moroni M, Contursi C et al. Electron transfer between cytochrome c and p66Shc generates reactive oxygen species that trigger mitochondrial apoptosis. Cell 2005; 122: 221–33.
- 11Wieckowski MR, Giorgi C, Lebiedzinska M, Duszynski J, Pinton P. Isolation of mitochondria-associated membranes and mitochondria from animal tissues and cells. Nat Protoc 2009; 4: 1582–90.
- 12Lebiedzinska M, Duszynski J, Rizzuto R, Pinton P, Wieckowski MR. Age-related changes in levels of p66Shc and serine 36-phosphorylated p66Shc in organs and mouse tissues. Arch Biochem Biophys 2009; 486: 73–80.
- 13Nemoto S, Finkel T. Redox regulation of forkhead proteins through a p66shc-dependent signaling pathway. Science 2002; 295: 2450–2.
- 14Beltrami E, Valtorta S, Moresco R, Marcu R, Belloli S, Fassina A et al. The p53-p66Shc apoptotic pathway is dispensable for tumor suppression whereas the p66Shc-generated oxidative stress initiates tumorigenesis. Curr Pharm Des 2013; 19: 2708–14.
- 15Migliaccio E, Giorgio M, Mele S, Pelicci G, Reboldi P, Pandolfi PP et al. The p66shc adaptor protein controls oxidative stress response and life span in mammals. Nature 1999; 402: 309–13.
- 16Pani G, Koch OR, Galeotti T. The p53-p66shc-Manganese Superoxide Dismutase (MnSOD) network: a mitochondrial intrigue to generate reactive oxygen species. Int J Biochem Cell Biol 2009; 41: 1002–5.
- 17Ma Z, Liu Z, Wu RF, Terada LS. p66(Shc) restrains Ras hyperactivation and suppresses metastatic behavior. Oncogene 2010; 29: 5559–67.
- 18Ventura A, Luzi L, Pacini S, Baldari CT, Pelicci PG. The p66Shc longevity gene is silenced through epigenetic modifications of an alternative promoter. J Biol Chem 2002; 277: 22370–6.
- 19Du W, Jiang Y, Zheng Z, Zhang Z, Chen N, Ma Z et al. Feedback loop between p66(Shc) and Nrf2 promotes lung cancer progression. Cancer Lett 2013; 337: 58–65.
- 20Zhou S, Chen HZ, Wan YZ, Zhang QJ, Wei YS, Huang S et al. Repression of P66Shc expression by SIRT1 contributes to the prevention of hyperglycemia-induced endothelial dysfunction. Circ Res 2011; 109: 639–48.
- 21Yuan H, Su L, Chen WY. The emerging and diverse roles of sirtuins in cancer: a clinical perspective. Onco Targets Ther 2013; 6: 1399–416.
- 22Jackson JG, Yoneda T, Clark GM, Yee D. Elevated levels of p66 Shc are found in breast cancer cell lines and primary tumors with high metastatic potential. Clin Cancer Res 2000; 6: 1135–9.
- 23Xie Y, Hung MC. p66Shc isoform down-regulated and not required for HER-2/neu signaling pathway in human breast cancer cell lines with HER-2/neu overexpression. Biochem Biophys Res Commun 1996; 221: 140–5.
- 24Davol PA, Bagdasaryan R, Elfenbein GJ, Maizel AL, Frackelton AR Jr. Shc proteins are strong, independent prognostic markers for both node-negative and node-positive primary breast cancer. Cancer Res 2003; 63: 6772–83.
- 25Frackelton AR Jr, Lu L, Davol PA, Bagdasaryan R, Hafer LJ, Sgroi DC. p66 Shc and tyrosine-phosphorylated Shc in primary breast tumors identify patients likely to relapse despite tamoxifen therapy. Breast Cancer Res 2006; 8: R73.
- 26Grossman SR, Lyle S, Resnick MB, Sabo E, Lis RT, Rosinha E et al. p66 Shc tumor levels show a strong prognostic correlation with disease outcome in stage IIA colon cancer. Clin Cancer Res 2007; 13: 5798–804.
- 27Lee MS, Igawa T, Chen SJ, Van Bemmel D, Lin JS, Lin FF et al. p66Shc protein is upregulated by steroid hormones in hormone-sensitive cancer cells and in primary prostate carcinomas. Int J Cancer 2004; 108: 672–8.
- 28Muniyan S, Chou YW, Tsai TJ, Thomes P, Veeramani S, Benigno BB et al. p66Shc longevity protein regulates the proliferation of human ovarian cancer cells. Mol Carcinog 2014; doi: 10.1002/mc.22129.
- 29Park YJ, Kim TY, Lee SH, Kim H, Kim SW, Shong M et al. p66Shc expression in proliferating thyroid cells is regulated by thyrotropin receptor signaling. Endocrinology 2005; 146: 2473–80.
- 30Rajendran M, Thomes P, Zhang L, Veeramani S, Lin MF. p66Shc–a longevity redox protein in human prostate cancer progression and metastasis: p66Shc in cancer progression and metastasis. Cancer Metastasis Rev 2010; 29: 207–22.
- 31Veeramani S, Yuan TC, Lin FF, Lin MF. Mitochondrial redox signaling by p66Shc is involved in regulating androgenic growth stimulation of human prostate cancer cells. Oncogene 2008; 27: 5057–68.
- 32Veeramani S, Igawa T, Yuan TC, Lin FF, Lee MS, Lin JS et al. Expression of p66(Shc) protein correlates with proliferation of human prostate cancer cells. Oncogene 2005; 24: 7203–12.
- 33Kumar S, Kumar S, Rajendran M, Alam SM, Lin FF, Cheng PW et al. Steroids up-regulate p66Shc longevity protein in growth regulation by inhibiting its ubiquitination. PLoS ONE 2011; 6: e15942.
- 34Capitani N, Lucherini OM, Sozzi E, Ferro M, Giommoni N, Finetti F et al. Impaired expression of p66Shc, a novel regulator of B-cell survival, in chronic lymphocytic leukemia. Blood 2010; 115: 3726–36.
- 35Kasuno K, Naqvi A, Dericco J, Yamamori T, Santhanam L, Mattagajasingh I et al. Antagonism of p66shc by melanoma inhibitory activity. Cell Death Differ 2007; 14: 1414–21.
- 36Galimov ER, Sidorenko AS, Tereshkova AV, Pletiushkina OIu, Cherniak BV, Chumakov PM. P66shc action on resistance of colon carcinoma RKO cells to oxidative stress. Mol Biol (Mosk) 2012; 46: 139–46.
- 37Zheng Z, Yang J, Zhao D, Gao D, Yan X, Yao Z et al. Downregulated adaptor protein p66(Shc) mitigates autophagy process by low nutrient and enhances apoptotic resistance in human lung adenocarcinoma A549 cells. FEBS J 2013; 280: 4522–30.
- 38Abdollahi A, Gruver BN, Patriotis C, Hamilton TC. Identification of epidermal growth factor-responsive genes in normal rat ovarian surface epithelial cells. Biochem Biophys Res Commun 2003; 307: 188–97.
- 39Soliman MA, Abdel Rahman AM, Lamming DW, Birsoy K, Pawling J, Frigolet ME et al. The adaptor protein p66Shc inhibits mTOR-dependent anabolic metabolism. Sci Signal 2014; 7: ra17.
- 40Um SH, D'Alessio D, Thomas G. Nutrient overload, insulin resistance, and ribosomal protein S6 kinase 1, S6K1. Cell Metab 2006; 3: 393–402.
- 41Pani G. P66SHC and ageing: ROS and TOR? Aging (Albany NY) 2010; 2: 514–8.
- 42Pani G, Galeotti T. Role of MnSOD and p66shc in mitochondrial response to p53. Antioxid Redox Signal 2011; 15: 1715–27.
- 43Ertel A, Verghese A, Byers SW, Ochs M, Tozeren A. Pathway-specific differences between tumor cell lines and normal and tumor tissue cells. Mol Cancer 2006; 5: 55.
- 44Sansone P, Storci G, Giovannini C, Pandolfi S, Pianetti S, Taffurelli M et al. p66Shc/Notch-3 interplay controls self-renewal and hypoxia survival in human stem/progenitor cells of the mammary gland expanded in vitro as mammospheres. Stem Cells 2007; 25: 807–15.
- 45Li X, Xu Z, Du W, Zhang Z, Wei Y, Wang H et al. Aiolos promotes anchorage independence by silencing p66Shc transcription in cancer cells. Cancer Cell 2014; 25: 575–89.
- 46Szatrowski TP, Nathan CF. Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res 1991; 51: 794–8.
- 47Veeramani S, Chou YW, Lin FC, Muniyan S, Lin FF, Kumar S et al. Reactive oxygen species induced by p66Shc longevity protein mediate nongenomic androgen action via tyrosine phosphorylation signaling to enhance tumorigenicity of prostate cancer cells. Free Radic Biol Med 2012; 53: 95–108.
